دورية أكاديمية
Analysis and comparison of SARS-CoV-2 variant antibodies and neutralizing activity for 6 months after a booster mRNA vaccine in a healthcare worker population.
| العنوان: | Analysis and comparison of SARS-CoV-2 variant antibodies and neutralizing activity for 6 months after a booster mRNA vaccine in a healthcare worker population. |
|---|---|
| المؤلفون: | Hosseinian S; School of Medicine, University of California Irvine, Irvine, CA, United States., de Assis R; Department of Physiology and Biophysics, University of California Irvine, Irvine, CA, United States., Khalil G; School of Medicine, University of California Irvine, Irvine, CA, United States., Luu MK; School of Biological Sciences, University of California Irvine, Irvine, CA, United States., Jain A; Department of Physiology and Biophysics, University of California Irvine, Irvine, CA, United States., Horvath P; Institute for Clinical and Translational Science, University of California Irvine, Irvine, CA, United States., Nakajima R; Department of Physiology and Biophysics, University of California Irvine, Irvine, CA, United States., Palma AM; Institute for Clinical and Translational Science, University of California Irvine, Irvine, CA, United States., Hoang A; School of Biological Sciences, University of California Irvine, Irvine, CA, United States., Razzak E; School of Biological Sciences, University of California Irvine, Irvine, CA, United States., Garcia N; School of Medicine, University of California Irvine, Irvine, CA, United States., Alger J; Institute for Clinical and Translational Science, University of California Irvine, Irvine, CA, United States., Kalantari M; Innovative Health Diagnostics, Irvine, CA, United States., Silzel EK; Department of Physiology and Biophysics, University of California Irvine, Irvine, CA, United States., Jasinskas A; Department of Physiology and Biophysics, University of California Irvine, Irvine, CA, United States., Zaldivar F; Department of Physiology and Biophysics, University of California Irvine, Irvine, CA, United States.; Department of Pediatrics, University of California Irvine, Irvine, CA, United States., Schubl SD; Department of Surgery, School of Medicine, University of California Irvine, Irvine, CA, United States., Felgner PL; Department of Physiology and Biophysics, University of California Irvine, Irvine, CA, United States., Khan S; Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States. |
| المصدر: | Frontiers in immunology [Front Immunol] 2023 May 17; Vol. 14, pp. 1166261. Date of Electronic Publication: 2023 May 17 (Print Publication: 2023). |
| نوع المنشور: | Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Intramural |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مواضيع طبية MeSH: | SARS-CoV-2* , COVID-19*/prevention & control, Humans ; Antibodies, Viral ; Health Personnel ; mRNA Vaccines |
| مستخلص: | Introduction: In the context of recurrent surges of SARS-CoV-2 infections, a detailed characterization of antibody persistence over a 6-month period following vaccine booster dose is necessary to crafting effective public health policies on repeat vaccination. Methods: To characterize the SARS-CoV-2 antibody profile of a healthcare worker population over a 6-month period following mRNA vaccination and booster dose. 323 healthcare workers at an academic medical center in Orange County, California who had completed primary vaccination and booster dose against SARS-CoV-2 were recruited for the study. A total of 690 blood specimens over a 6-month period were collected via finger-stick blood and analyzed for the presence of antibodies against 9 SARS-CoV-2 antigens using a coronavirus antigen microarray. Results: The primary outcome of this study was the average SARS-CoV-2 antibody level as measured using a novel coronavirus antigen microarray. Additional outcomes measured include levels of antibodies specific to SARS-CoV-2 variants including Delta, Omicron BA.1, and BA.2. We also measured SARS-CoV-2 neutralization capacity for a subset of the population to confirm correlation with antibody levels. Although antibodies against SARS-CoV-2 wane throughout the 6-month period following a booster dose, antibody levels remain higher than pre-boost levels. However, a booster dose of vaccine based on the original Wuhan strain generates approximately 3-fold lower antibody reactivity against Omicron variants BA.1 and BA.2 as compared to the vaccine strain. Despite waning antibody levels, neutralization activity against the vaccine strain is maintained throughout the 6-month period. Discussion: In the context of recurrent surges of SARS-CoV-2 infections, our data indicate that breakthrough infections are likely driven by novel variants with different antibody specificity and not by time since last dose of vaccination, indicating that development of vaccinations specific to these novel variants is necessary to prevent future surges of SARS-CoV-2 infections. Competing Interests: The coronavirus antigen microarray is intellectual property of the Regents of the University of California that is licensed for commercialization to Nanommune Inc. Irvine, CA, a private company for which PF is the largest shareholder and several co-authors RA, AaJ, RN, and SK also own shares. Nanommune Inc. has a business partnership with Sino Biological Inc. Beijing, China which expressed and purified the antigens used in this study. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Hosseinian, de Assis, Khalil, Luu, Jain, Horvath, Nakajima, Palma, Hoang, Razzak, Garcia, Alger, Kalantari, Silzel, Jasinskas, Zaldivar, Schubl, Felgner and Khan.) |
| التعليقات: | Update of: Res Sq. 2022 Dec 14;:. (PMID: 36561177) |
| References: | Nat Commun. 2021 Jan 4;12(1):6. (PMID: 33397903) Front Immunol. 2023 Feb 28;14:1123158. (PMID: 36926327) Nature. 2021 May;593(7857):142-146. (PMID: 33780970) JAMA. 2021 Dec 7;326(21):2203-2204. (PMID: 34739043) Lancet. 2021 Dec 4;398(10316):2093-2100. (PMID: 34756184) Front Immunol. 2022 Apr 12;13:817345. (PMID: 35493473) Nature. 2022 Jul;607(7918):351-355. (PMID: 35584773) Diagn Microbiol Infect Dis. 2021 Apr;99(4):115294. (PMID: 33387896) N Engl J Med. 2021 Dec 9;385(24):e84. (PMID: 34614326) Viruses. 2022 Sep 13;14(9):. (PMID: 36146829) Nat Med. 2021 Jul;27(7):1205-1211. (PMID: 34002089) Cell Discov. 2022 Jan 17;8(1):4. (PMID: 35034952) Nat Commun. 2022 Apr 13;13(1):1971. (PMID: 35418201) Lancet. 2020 Nov 14;396(10262):1595-1606. (PMID: 33065034) N Engl J Med. 2020 Dec 31;383(27):2603-2615. (PMID: 33301246) N Engl J Med. 2021 Oct 21;385(17):1627-1629. (PMID: 34525276) N Engl J Med. 2021 Dec 9;385(24):e85. (PMID: 34706170) Nat Biotechnol. 2020 Sep;38(9):1073-1078. (PMID: 32704169) N Engl J Med. 2022 Feb 3;386(5):492-494. (PMID: 34965337) N Engl J Med. 2021 Feb 4;384(5):403-416. (PMID: 33378609) Lancet Respir Med. 2021 Jul;9(7):712-720. (PMID: 33865504) Infect Dis Ther. 2021 Sep;10(3):1505-1518. (PMID: 34137000) Science. 2022 Feb 11;375(6581):678-680. (PMID: 35040667) |
| معلومات مُعتمدة: | KL2 TR001416 United States TR NCATS NIH HHS; P30 CA062203 United States CA NCI NIH HHS; T35 DK128788 United States DK NIDDK NIH HHS; UL1 TR001414 United States TR NCATS NIH HHS |
| فهرسة مساهمة: | Keywords: SARS-CoV-2; healthcare worker (HCW); mRNA; serology; vaccine |
| المشرفين على المادة: | 0 (Antibodies, Viral) |
| SCR Organism: | SARS-CoV-2 variants |
| تواريخ الأحداث: | Date Created: 20230602 Date Completed: 20230605 Latest Revision: 20231213 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC10229859 |
| DOI: | 10.3389/fimmu.2023.1166261 |
| PMID: | 37266444 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2023.1166261 |